Economic information and modeling reportBudget impact model
Cost assumptions
8 evidence topics · 7 sources
Medicare Part B payment limits for parenteral comparators and bone-targeted agents, October to December 2026
| HCPCS code and product | Short description | HCPCS code dosage | Payment limit (USD) | Coinsurance percentage |
|---|---|---|---|---|
| J9043 cabazitaxel (Jevtana) | “Cabazitaxel injection” | “1 MG” | “231.688” | “20.000” |
| J9171 docetaxel | “Docetaxel injection” | “1 MG” | “0.471” | “20.000” |
| Q2043 sipuleucel-T (Provenge) | “Sipuleucel-t auto cd54+” | “Per infusion (minimum 50 million cells)” | “55663.131” | “20.000” |
| J9271 pembrolizumab (Keytruda) | “Inj pembrolizumab” | “1 MG” | “62.253” | “20.000” |
| J0897 denosumab (Xgeva) | “Denosumab injection” | “1 MG” | “29.856” | “17.885” |
| J3489 zoledronic acid | “Zoledronic acid 1mg” | “1 MG” | “17.673” | “20.000” |
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1 microCurie” | “N/A” | “20.000” |
Radium-223 dichloride: payment limit note in the Medicare Part B file
Hospital outpatient payment rates for radiopharmaceuticals, October 2026
| HCPCS code and product | Short descriptor | APC | Payment rate | Minimum unadjusted copayment |
|---|---|---|---|---|
| A9606 radium-223 dichloride (Xofigo) | “Radium ra223 dichloride ther” | “1745” | “$180.422” | “$36.09” |
| A9607 lutetium Lu 177 vipivotide tetraxetan (Pluvicto) | “Lutetium lu 177 vipivotide” | “9054” | “$266.541” | “$53.31” |
Lutetium Lu 177 vipivotide tetraxetan: per-dose cost estimated from Medicare Administrative Contractor payment rates
“We collected all identifiable MAC payment rates for 177Lu-PSMA-617 (HCPCS A9607) across publicly available MAC jurisdictions (JE, JF, JJ, JM, J6, JK, and J15), standardized rates to a per-millicurie basis, and used the median to reduce outlier influence. Assuming the use of a 200-mCi dose, this yielded an estimated per-dose cost of $55,522 (3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although 177Lu-PSMA-617 was approved by the Food and Drug Administration in March 2022 (7), there remains no ASP-based benchmark for this agent within the CMS ASP framework; under the current reimbursement structure, such a benchmark would not be expected to emerge absent U.S. legislative or regulatory change (4–6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Per-cycle costs in the U.S. lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel model
| Input | Base case value (USD) | Range for sensitivity analysis (USD) |
|---|---|---|
| Cost per cycle, lutetium Lu 177 vipivotide tetraxetan | “32,062”View highlighted excerpt for this quote | “25,649–38,474”View highlighted excerpt for this quote |
| Cost per cycle, cabazitaxel | “14,382”View highlighted excerpt for this quote | “11,505–17,852”View highlighted excerpt for this quote |
| Gallium Ga 68 PSMA PET/CT | “5,689”View highlighted excerpt for this quote | “4,551–6,829”View highlighted excerpt for this quote |
| End of life | “17,312”View highlighted excerpt for this quote | “13,849–20,773”View highlighted excerpt for this quote |
Darolutamide wholesale acquisition cost
| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
|---|---|---|---|---|---|
| Nubeqa (darolutamide) 300 mg, 120 tablets | “Bayer” | “Nubeqa 300 mg tab 120 count” | “2026-01-01T00:00:00” | “847.20” | “15100.80” |
Enzalutamide: Medicare negotiated price effective January 2027 and 2024 list price
| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2027 | List price for 30-day supply, CY 2024 | Discount of negotiated price from 2024 list price |
|---|---|---|---|---|
| Xtandi (enzalutamide) | “Astellas Pharma US, Inc.” | “$7,004” | “$13,480” | “48%” |